c-LEcta GmbH. (1/26/17). "Press Release: c-LEcta Starts Marketing & Distribution of Denarase".

	Organisation	c-LEcta GmbH
	Group	Kerry Group (Group)
	Organisation 2	Sartorius Stedim Biotech GmbH (SSB)
	Group	Sartorius (Group)
	Product	Denarase®
	Product 2	biopharmaceutical

DENARASE® is now directly available at c-LEcta. c-LEcta has taken over the product distribution from Sartorius Stedim Biotech GmbH by the end of 2016 and now sells DENARASE® under the same brand name and in identical package sizes. Furthermore, c-LEcta continues to produce the endonuclease in the same production facilities using its patent protected production process in full compliance with cGMP requirements. This process allows to provide DENARASE® in an outstanding product quality and at low prices.

DENARASE® from Serratia marcenses is a highly active nuclease that is used to remove interfering DNA and RNA from fermentation batches e.g. during the production of vaccines and biopharmaceuticals.

The advantages of DENARASE® are:

+ Animal product free production

+ endotoxin-free production strain

+ high purity and activity

+ compliance with cGMP

If you are interested in testing our DENARASE or if you need further information, please do not hesitate to contact us via denarase@c-lecta.com.

Record changed: 2023-06-05